Longitudinal Changes in Tenofovir and Tenofovir Diphosphate Concentrations Among Pregnant Women Using Oral PrEP for HIV Prevention: Findings From Durban, South Africa.

Journal: Journal of acquired immune deficiency syndromes (1999)

Volume: 98

Issue: 4

Year of Publication: 2025

Affiliated Institutions:  Division of Infectious Diseases, University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, AL. Wits Maternal Adolescent and Child Health Research Unit (WMRU), Department of Obstetrics and Gynaecology, Faculty of Health Sciences, University of the Witwatersrand, Durban, KwaZulu-Natal, South Africa. Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA. Department of Medicine (Clinical Pharmacology), Johns Hopkins University, School of Medicine, Baltimore, MD. Behavioural Medicine Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA; and. Vin University College of Health Sciences, Hanoi, Vietnam .

Abstract summary 

Pregnant women are vulnerable to HIV acquisition. Oral HIV pre-exposure prophylaxis (PrEP) is safe and effective for use during pregnancy. We describe PrEP adherence among pregnant women using multiple measures.We conducted a secondary data analysis among women enrolled in a study evaluating an adherence intervention for PrEP among those planning for and with pregnancy in South Africa. Our analysis included women who used PrEP and became pregnant. Longitudinal PrEP use was assessed using concentrations of tenofovir (TFV) in plasma, tenofovir diphosphate (TFV-DP) in dried blood spots, and electronic pillcap data from quarterly visits. Plasma TFV ≤10 ng/mL and TFV-DP ≤16.6 fmol/punch were below quantifiable limits. Data were analyzed during prepregnancy (quarter before pregnancy) and pregnancy trimesters.Among 35 women, 69% were 18-24 years old, 40% were nulliparous, and 94% did not know their partner's HIV serostatus. Median pillcap adherence was 55%-80% and was highest during prepregnancy (72%, interquartile range: 54%-86%) and third trimester (80%, interquartile range: 30%-94%). The proportion of women with quantifiable TFV was 47% (n = 8/17) prepregnancy and 33% (n = 9/27), 19% (n = 4/21), and 14% (n = 2/14) for trimesters 1-3, respectively. TFV-DP was detected in 75% of samples (n = 12/16) prepregnancy, and 50% (n = 13/26), 29% (n = 6/21), and 27% (n = 4/15) for trimesters 1-3, respectively. No women acquired HIV during pregnancy.PrEP use declined during pregnancy by all measures. Discrepancies between pillcap measurements and drug concentrations could be due to physiologic changes during pregnancy or under- or overuse of the pillcaps. Determining what drug metabolite concentrations are needed to confer protection during pregnancy is important for optimizing counseling and prevention support.

Authors & Co-authors:  Beesham Ivana I Jaggernath Manjeetha M Kriel Yolandie Y Hao Jiaying J Smith Patricia M PM Haberer Jessica E JE Hendrix Craig W CW Psaros Christina C Bangsberg David R DR Smit Jennifer A JA Matthews Lynn T LT

Study Outcome 

Source Link: Visit source

Statistics
Citations :  UNAIDS. Country Fact Sheets: South Africa. Available at: https://www.unaids.org/en/regionscountries/countries/southafrica . Accessed September 05, 2022.
Authors :  11
Identifiers
Doi : 10.1097/QAI.0000000000003586
SSN : 1944-7884
Study Population
Female,Women
Mesh Terms
Humans
Other Terms
Study Design
Longitudinal Study
Study Approach
Country of Study
South Africa
Publication Country
United States